Bionik Laboratories Corp. recently announced its board of directors has appointed Eric Dusseux, MD, MSc, MBA, as chief executive officer, effective Sept. 1.
Dusseux had served as director of the company since July. He has 15 years of experience in the health care sector. He most recently served as president of Europe at Auregen BioTherapeutics SA, a 3-D bioprinting tissue-engineering biotechnology company, that he formed while at Bemido SA, according to a press release from Bionik.
The company announced Peter Bloch will continue to serve the company as chairman of the board of directors and will consult with the company during the management transaction.
“We are delighted that Eric has chosen to accept the role of chief executive officer at Bionik,” Bloch said in the release. “His proven entrepreneurial ability to drive commercialization and growth strategy in domestic and international markets, and his experience in building and leading strategic alliances will be significant assets for Bionik. Eric’s appointment coincides with our efforts to expand our global sales and marketing efforts and develop strategic distribution agreements and partnerships targeting hospital and mass markets.”
Dusseux, who has specialized in public health, also has worked for Sanofi Pasteur and the immunotherapeutics business unit at GSK Biologicals, a division of GlaxoSmithKline.
“I am excited to be joining the management team of Bionik at a very important time for the company,” Dusseux said in the release “… I look forward to broadening our innovative clinical product platform and helping to bring our products under development from the hospital to the home as we pursue mass market opportunities.”